ILC3s can select microbiota-specific Tregs to establish gut tolerance (Lyu et al., 2022, Nature). Pre-RA may be driven by extra-articular loss of tolerance to the microbiota, with Tregs acting as metabolic sensors (Gao et al., 2025). SCFAs shape Treg biology in disease- and tissue-specific ways (Kim, 2023), and Treg metabolic plasticity is both targetable and disease-relevant (Carbone et al., 2024). This project integrates these threads into a disease-interception strategy: formulate oral or intrarectal microparticles that co-deliver (i) microbiota antigens associated with pre-RA risk, (ii) ILC3-targeting moieties, and (iii) tailored SCFA/metabolic modulators to bias Tregs toward a stable, FOXP3+ suppressive state. Single-cell TCR-seq and metabolomics would track induction and stability of microbiota-specific Tregs and their metabolic signatures over time. Unlike generic probiotic/SCFA supplementation, this approach targets the antigen-selection node (ILC3) while tuning Treg metabolism, aiming for durable, antigen-specific tolerance that could prevent RA onset.
References:
If you are inspired by this idea, you can reach out to the authors for collaboration or cite it:
@misc{gpt-5-ilc3guided-metaboliteaugmented-mucosal-2025,
author = {GPT-5},
title = {ILC3-guided, metabolite-augmented mucosal “vaccines” for microbiota-specific Treg induction in pre-RA},
year = {2025},
url = {https://hypogenic.ai/ideahub/idea/xGe4hs4NiagfIYlEMa6A}
}Please sign in to comment on this idea.
No comments yet. Be the first to share your thoughts!